文献速递浆细胞疾病

通过质谱法筛查的美国高危人群中单克隆丙种球蛋白病的患病率与临床结局:一项多中心队列研究

Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
PubMed 文献 · Lancet Haematol · 2022-03-25

该多中心队列研究采用定量MALDI-TOF质谱法筛查7622名高危个体的血清,发现50岁及以上高危人群中质谱法单克隆丙种球蛋白病总患病率为43%,其中质谱法MGUS为13%,并定义低于免疫固定电泳检测水平的MGIP。筛查检出的单克隆丙种球蛋白病与全因死亡率升高相关(HR 1.55)。

要点

  • 50岁及以上高危人群质谱法单克隆丙种球蛋白病总患病率为43%。
  • 质谱法MGUS患病率随年龄增长而升高,男性高于女性。
  • 筛查检出的单克隆丙种球蛋白病与全因死亡率升高相关(HR 1.55)。

核心结论

  • 研究在高危人群中检出高患病率的单克隆丙种球蛋白病,包括与年龄相关的MGIP,并较传统凝胶法更精确地估算了质谱法MGUS。
  • 质谱法的使用凸显了MGIP可能隐藏的临床意义。
  • 研究提示单克隆丙种球蛋白病与多种临床表型及总生存期降低相关。

研究设计与样本

  • 多中心队列研究,纳入2019年2月26日至2021年11月4日同意参加PROMISE筛查研究的个体及2010年7月28日至2021年7月1日Mass General Brigham Biobank(MGBB)的个体,共7622人。
  • 采用定量基质辅助激光解吸电离飞行时间(MALDI-TOF)质谱法和EXENT-iQ软件筛查并定量血清单克隆丙种球蛋白病。
  • MGIP水平的M蛋白浓度通过液相色谱质谱法确认。
  • 6305名(83%;PROMISE 2211名,MGBB 4094名)参与者基于黑人种族或血液系统恶性肿瘤家族史被判定为单克隆丙种球蛋白病高危,且处于符合条件的高危年龄范围(PROMISE队列≥30岁,MGBB队列≥18岁)。
  • PROMISE队列中18岁以上且有两名或以上家庭成员患血癌者亦符合条件;筛查前已诊断浆细胞恶性肿瘤者被排除。

主要发现

  • 筛查时中位年龄为56.0岁(IQR 46.8-64.1);7622名参与者中女性5013名(66%),男性2570名(34%),未知39名(<1%)。
  • 2439名(32%)自认为黑人,4986名(65%)自认为白人,119名(2%)为其他,78名(1%)未知。
  • 在50岁及以上高危个体中,采用血清蛋白电泳联合免疫固定电泳的MGUS患病率为6%(101/1714),而采用质谱法的单克隆丙种球蛋白病总患病率为43%(1788/4207)。
  • 质谱法MGUS(浓度≥0.2 g/L)在50岁及以上高危个体中的患病率为13%(592/4207)。
  • MGIP(浓度<0.2 g/L)以免疫球蛋白M同种型为主,其患病率随年龄增长而升高:<50岁为19%(488/2564),≥50岁为29%(1464/5058),≥70岁为37%(347/946)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is reported for MGUS in the general population of European ancestry aged 50 years or older. MGUS prevalence is two times higher in individuals of African descent or with a family history of conditions related to multiple myeloma. We aimed to evaluate the prevalence and clinical implications of monoclonal gammopathies in a high-risk US population screened by quantitative mass spectrometry. METHODS: We used quantitative matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) mass spectrometry and EXENT-iQ software to screen for and quantify monoclonal gammopathies in serum from 7622 individuals who consented to the PROMISE screening study between Feb 26, 2019, and Nov 4, 2021, and the Mass General Brigham Biobank (MGBB) between July 28, 2010, and July 1, 2021. M-protein concentrations at the monoclonal gammopathy of indeterminate potential (MGIP) level were confirmed by liquid chromatography mass spectrometry testing. 6305 (83%; 2211 from PROMISE, 4094 from MGBB) of 7622 participants in the cohorts were at high risk for developing a monoclonal gammopathy on the basis of Black race or a family history of haematological malignancies and fell within the eligible high-risk age range (30 years or older for PROMISE cohort and 18 years or older for MGBB cohort); those over 18 years were also eligible if they had two or more family members with a blood cancer (PROMISE cohort). Participants with a plasma cell malignancy diagnosed before screening were excluded. Longitudinal clinical data were available for MGBB participants with a median follow-up time from serum sample screening of 4·5 years (IQR 2·4-6·7). The PROMISE study is registered with ClinicalTrials.gov, NCT03689595. FINDINGS: The median age at time of screening was 56·0 years (IQR 46·8-64·1). 5013 (66%) of 7622 participants were female, 2570 (34%) male, and 39 (<1%) unknown. 2439 (32%) self-identified as Black, 4986 (65%) as White, 119 (2%) as other, and 78 (1%) unknown. Using serum protein electrophoresis with immunofixation electrophoresis, the MGUS prevalence was 6% (101 of 1714) in high-risk individuals aged 50 years or older. Using mass spectrometry, we observed a total prevalence of monoclonal gammopathies of 43% (1788 of 4207) in this group. We termed monoclonal gammopathies below the clinical immunofixation electrophoresis detection level (<0·2 g/L) MGIPs, to differentiate them from those with higher concentrations, termed mass-spectrometry MGUS, which had a 13% (592 of 4207) prevalence by mass spectrometry in high-risk individuals aged 50 years or older. MGIP was predominantly of immunoglobulin M isotype, and its prevalence increased with age (19% [488 of 2564] for individuals aged <50 years, 29% [1464 of 5058] for those aged ≥50 years, and 37% [347 of 946] for those aged ≥70 years). Mass-spectrometry MGUS prevalence increased with age (5% [127 of 2564] for individuals aged <50 years, 13% [678 of 5058] for those aged ≥50 years, and 18% [173 of 946] for those aged ≥70 years) and was higher in men (314 [12%] of 2570) compared with women (485 [10%] 5013; p=0·0002), whereas MGIP prevalence did not differ significantly by gender. In those aged 50 years or older, the prevalence of mass spectrometry was significantly higher in Black participants (224 [17%] of 1356) compared with the controls (p=0·0012) but not in those with family history (368 [13%] of 2851) compared with the controls (p=0·1008). Screen-detected monoclonal gammopathies correlated with increased all-cause mortality in MGBB participants (hazard ratio 1·55, 95% CI 1·16-2·08; p=0·0035). All monoclonal gammopathies were associated with an increased likelihood of comorbidities, including myocardial infarction (odds ratio 1·60, 95% CI 1·26-2·02; p=0·00016 for MGIP-high and 1·39, 1·07-1·80; p=0·015 for mass-spectrometry MGUS). INTERPRETATION: We detected a high prevalence of monoclonal gammopathies, including age-associated MGIP, and made more precise estimates of mass-spectrometry MGUS compared with conventional gel-based methods. The use of mass spectrometry also highlighted the potential hidden clinical significance of MGIP. Our study suggests the association of monoclonal gammopathies with a variety of clinical phenotypes and decreased overall survival. FUNDING: Stand Up To Cancer Dream Team, the Multiple Myeloma Research Foundation, and National Institutes of Health.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. El-Khoury H, Lee DJ, Alberge JB, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022. PMID: 35344689. doi:10.1016/S2352-3026(22)00069-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。